Safety and efficacy of PD-1 inhibitors versus chemotherapy or ipilimumab in advanced melanoma:Meta-analysis
10.3969/j.issn.1000-484X.2024.01.021
- VernacularTitle:PD-1抑制剂对比化疗或伊匹单抗治疗晚期黑色素瘤安全性和有效性的Meta分析
- Author:
Zhibing LIN
1
;
Yazhen MAO
;
Xiaoyan ZHOU
;
Xiaodan LIN
;
Guiqiu XU
;
Wei LIN
;
Yuhong LIN
Author Information
1. 福建医科大学附属福州市第一医院检验科,福州 350009
- Keywords:
PD-1;
Nivolumab;
Pembrolizumab;
Ipilimumab;
Advanced melanoma;
Meta-analysis
- From:
Chinese Journal of Immunology
2024;40(1):138-143,中插1-中插7
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the safety and efficacy of PD-1 inhibitors versus chemotherapy or ipilimumab in advanced melanoma.Methods:PubMed,CNKI,VIP and Wanfang databases were searched to collect randomised controlled trials of PD-1 inhibi-tors in treatment of advanced melanoma.The search time was from the establishment of the database to May 1,2022.Two reviewers independently screened the literature,extracted data,and assessed risk of bias of included studies.Meta-analysis was performed using RevMan5.4 and STATA16 software.Results:A total of 7 studies were included.Meta-analysis results show that:①Safety:Compared with chemotherapy,PD-1 inhibitor treatment had fewer adverse events,especially in the blood system;compared with ipilimumab alone,PD-1 inhibitor combined with ipilimumab had more adverse events,especially liver function indicators;there was no signifi-cant difference in the incidence of total adverse events between PD-1 inhibitor monotherapy and ipilimumab monotherapy.②Efficacy:The PFS,OS and ORR of PD-1 inhibitor versus chemotherapy or ipilimumab were HR=0.54,95%CI(0.45,0.62),P<0.05,HR= 0.69,95%CI(0.58,0.80),P=0.03 and OR=3.16,95%CI(2.59,3.86),P<0.05,respectively.Conclusion:PD-1 inhibitors have good efficacy in treatment of advanced melanoma,while different combination methods and different control treatments may have different efficacy.Limited by the quantity and quality of included studies,more research evidence is needed to support this.
